Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, applied and pharmaceutical applications Promega ...

DelveInsight's DNA Synthesis Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Lower HCRU and costs may be reflective of improved patient care.

In patients with HIV infection, continuing or discontinuing abacavir in the dolutegravir/lamivudine combination is linked to ...

The study introduced LIME-seq, a new non-invasive technique capable of detecting RNA modifications at a detailed level across ...

Promega Corporation has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase. Designed for enhanced accuracy and sensitivity in RNA analysis, ...

The error rate of a promising gene-editing tool can be reduced up to 60-fold by introducing mutations that change where the ...

In 2003, the Nobel Prize winner David Baltimore, then president of Caltech, paused to reflect on his role as one of the world’s most decorated scientists. “People keep e-mailing me to ask, ‘What is ...

The DNA synthesis inhibitors market is projected to witness substantial growth in the coming years, driven by the rising incidence of cancer diagnoses, growing awareness, the expanding pipeline ...

Close monitoring of HIV viral load is crucial to prevent LLV among HIV-positive patients on ART, particularly older adults with low CD4+ counts and a history of PI use.

Junk DNA” may hold the key to treating tough cancers. Existing drugs exploit weaknesses in cells with gene mutations. Researchers at King’s College London have identified a promising strategy for ...